9d ago
Non-inferior survival and enhanced longevity with initial low-dose versus full-dose enzalutamide: a single-centre real-world prostate cancer study
Gorobets · O. · Vinh-Hung · V.
Abstract
Background: Prostate cancer enzalutamide treatment is approved at a standard dose of 160 mg daily. Concerns for real-world patients – older and more fragile than those enrolled in clinical trials – have prompted consideration of initiating treatment with lower doses, but the long-term efficacy of this approach remains unknown. We evaluate the long-term survival and longevity in patients treated with standard versus upfront low-dose enzalutamide. Methods: Retrospective analysis of 151 patients
Discussion · 0
Sign in to join the discussion.